PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine

• Published in: PR Newswire
• Format: Newsletter
• Language: English
• Published: New York PR Newswire Association LLC 01.02.2010
• Subjects: Anthrax; Antigens; Biological & chemical weapons; Candidates; Clinical trials; Funding; Human subjects; Mortality; Product development; R&D; Research & development; Vaccines; ANNAPOLIS, Md

Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").